Prostate adenocarcinoma represents the most common form of prostate cancer, affecting nearly all cases diagnosed in men. This specific type develops in the gland cells that produce prostate fluid, ...

Note benign prostatic glands for comparison on the left (a) (×200). Cribriform pattern is not recognized as HGPIN in the 5 th edition. On immunostain, HGPIN is positive for racemase and basal cell ...

Stage 2 prostate adenocarcinoma is localized, with a nearly 100%, five-year relative survival rate. Diagnosis uses the TNM system, PSA levels and Gleason score to determine cancer stage and risk.

The FOXA1 protein is a potentially highly sensitive diagnostic marker for small cell carcinoma of the prostate and possibly ...

Stage 1 prostate adenocarcinoma is localized, non-aggressive, and often detected through routine screenings like PSA tests and DREs. Diagnosis involves PSA levels, Gleason scores, and possibly ...

A liquid biopsy targeted proteomic assay to predict outcomes in castration resistant prostate cancer patients treated with 177Lu-PSMA-617. This is an ASCO Meeting Abstract from the 2026 ASCO ...

Grade group 1 and ASAP on prostate biopsy predict future prostate cancer risk and should not be ignored. Prostate biopsy findings of Gleason grade group (GG) 1 or atypical small acinar proliferation ...

Transdermal estradiol (tE2) is an alternative to luteinizing hormone–releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is ...

IsoPSA in prostate cancer: A systematic review of diagnostic, prognostic and economic implications. 1-Mann-Whitney U test, 2-Chi-square test. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...